BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 11212898)

  • 1. Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors.
    Schiebe M; Ohneseit P; Hoffmann W; Meyermann R; Rodemann HP; Bamberg M
    J Neurooncol; 2000 Sep; 49(3):197-203. PubMed ID: 11212898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas.
    Biernat W; Kleihues P; Yonekawa Y; Ohgaki H
    J Neuropathol Exp Neurol; 1997 Feb; 56(2):180-5. PubMed ID: 9034372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
    Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
    Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.
    Reifenberger G; Liu L; Ichimura K; Schmidt EE; Collins VP
    Cancer Res; 1993 Jun; 53(12):2736-9. PubMed ID: 8504413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of heterozygosity at 11p15 and p53 alterations in malignant gliomas.
    Schiebe M; Ohneseit P; Hoffmann W; Meyermann R; Rodemann HP; Bamberg M
    J Cancer Res Clin Oncol; 2001 May; 127(5):325-8. PubMed ID: 11355148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular genetic changes in a series of neuroepithelial tumors of childhood.
    Di Sapio A; Morra I; Pradotto L; Guido M; Schiffer D; Mauro A
    J Neurooncol; 2002 Sep; 59(2):117-22. PubMed ID: 12241104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
    Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O
    J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
    Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
    Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered patterns of MDM2 and TP53 expression in human bladder cancer.
    Lianes P; Orlow I; Zhang ZF; Oliva MR; Sarkis AS; Reuter VE; Cordon-Cardo C
    J Natl Cancer Inst; 1994 Sep; 86(17):1325-30. PubMed ID: 8064890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway.
    Das A; Tan WL; Teo J; Smith DR
    J Neurooncol; 2002 Nov; 60(2):117-25. PubMed ID: 12635658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
    Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.
    Shibagaki I; Tanaka H; Shimada Y; Wagata T; Ikenaga M; Imamura M; Ishizaki K
    Clin Cancer Res; 1995 Jul; 1(7):769-73. PubMed ID: 9816044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MDM2 gene amplification database.
    Momand J; Jung D; Wilczynski S; Niland J
    Nucleic Acids Res; 1998 Aug; 26(15):3453-9. PubMed ID: 9671804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations.
    Cuny M; Kramar A; Courjal F; Johannsdottir V; Iacopetta B; Fontaine H; Grenier J; Culine S; Theillet C
    Cancer Res; 2000 Feb; 60(4):1077-83. PubMed ID: 10706127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.
    Habuchi T; Kinoshita H; Yamada H; Kakehi Y; Ogawa O; Wu WJ; Takahashi R; Sugiyama T; Yoshida O
    J Natl Cancer Inst; 1994 Sep; 86(17):1331-5. PubMed ID: 8064891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
    Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
    Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of molecular markers in a series of 220 primary glioblastomas.
    Houillier C; Lejeune J; Benouaich-Amiel A; Laigle-Donadey F; Criniere E; Mokhtari K; Thillet J; Delattre JY; Hoang-Xuan K; Sanson M
    Cancer; 2006 May; 106(10):2218-23. PubMed ID: 16568472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets.
    Ghimenti C; Fiano V; Chiadò-Piat L; Chiò A; Cavalla P; Schiffer D
    J Neurooncol; 2003 Jan; 61(2):95-102. PubMed ID: 12622447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
    Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.